ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.29
31.77
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ACAD stock under the Base Case scenario is 19.77 USD. Compared to the current market price of 16.37 USD, ACADIA Pharmaceuticals Inc is Undervalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
ACADIA Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ACAD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
ACADIA Pharmaceuticals Inc
Balance Sheet Decomposition
ACADIA Pharmaceuticals Inc
Current Assets | 788.3m |
Cash & Short-Term Investments | 565.3m |
Receivables | 110.4m |
Other Current Assets | 112.6m |
Non-Current Assets | 188.6m |
PP&E | 48.2m |
Intangibles | 105.5m |
Other Non-Current Assets | 34.8m |
Current Liabilities | 343.9m |
Accounts Payable | 19.1m |
Accrued Liabilities | 324.9m |
Non-Current Liabilities | 55.7m |
Other Non-Current Liabilities | 55.7m |
Earnings Waterfall
ACADIA Pharmaceuticals Inc
Revenue
|
929.2m
USD
|
Cost of Revenue
|
-77.9m
USD
|
Gross Profit
|
851.3m
USD
|
Operating Expenses
|
-739.1m
USD
|
Operating Income
|
112.2m
USD
|
Other Expenses
|
16.3m
USD
|
Net Income
|
128.5m
USD
|
Free Cash Flow Analysis
ACADIA Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Acadia Pharmaceuticals experienced a solid third quarter, generating $250.4 million in net sales, up 18% year-over-year. Key products include Daybue with sales of $91.2 million and NUPLAZID at $159.2 million, both seeing growth due to increased patient engagement. The company has narrowed its guidance for Daybue to $340-$350 million and NUPLAZID to $600-$610 million for the year. Notably, a $150 million priority review voucher sale is expected to enhance cash flow, projecting a cash balance increase to $600-$640 million. Promising pipeline assets like ACP-101 and ACP-204 are in late-stage trials, supporting potential future growth.
What is Earnings Call?
ACAD Profitability Score
Profitability Due Diligence
ACADIA Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
ACADIA Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
ACAD Solvency Score
Solvency Due Diligence
ACADIA Pharmaceuticals Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
ACADIA Pharmaceuticals Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACAD Price Targets Summary
ACADIA Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ACAD is 25.61 USD with a low forecast of 11.11 USD and a high forecast of 40.95 USD.
Dividends
Current shareholder yield for ACAD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ACAD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
Contact
IPO
Employees
Officers
The intrinsic value of one ACAD stock under the Base Case scenario is 19.77 USD.
Compared to the current market price of 16.37 USD, ACADIA Pharmaceuticals Inc is Undervalued by 17%.